Study Details

Back
Study ID 8273-CL-0112
Study Title A Phase 1, Randomized, 2-period Crossover Study to Assess Bioequivalence of a Tablet Formulation versus a Capsule Formulation of ASP8273 in Subjects With Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations
Clinicaltrials.gov Identifier NCT03082300
Compound Name ASP8273 / naquotinib mesilate
Medical Indication or Disease Non-small cell lung cancer
Study Sponsor Astellas Pharma Global Development, Inc.
Collaborator Not Applicable
Study Start Date 24-Mar-2017
Study Completion Date 19-Jun-2017
Clinical Study Result
Select the language
English
Plain Language Summary
Select the language
English

QUICK SEARCH

USEFUL LINKS